OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1195-1204
Open Access | Times Cited: 25
Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1195-1204
Open Access | Times Cited: 25
Showing 25 citing articles:
Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma
Zhiyuan Wang, Xiaoyu Ji, Ye Zhang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 5, pp. e008983-e008983
Open Access | Times Cited: 8
Zhiyuan Wang, Xiaoyu Ji, Ye Zhang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 5, pp. e008983-e008983
Open Access | Times Cited: 8
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management
Marco Raffaelli, Nikolaos Voloudakis, Marcin Barczyński, et al.
British journal of surgery (2024) Vol. 111, Iss. 8
Open Access | Times Cited: 7
Marco Raffaelli, Nikolaos Voloudakis, Marcin Barczyński, et al.
British journal of surgery (2024) Vol. 111, Iss. 8
Open Access | Times Cited: 7
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Özgür Mete, Andrée Boucher, Kasmintan A. Schrader, et al.
Endocrine Pathology (2024)
Open Access | Times Cited: 7
Özgür Mete, Andrée Boucher, Kasmintan A. Schrader, et al.
Endocrine Pathology (2024)
Open Access | Times Cited: 7
An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer
Karen Yun, Ezra E.W. Cohen
JCO Oncology Practice (2024) Vol. 20, Iss. 7, pp. 899-906
Closed Access | Times Cited: 4
Karen Yun, Ezra E.W. Cohen
JCO Oncology Practice (2024) Vol. 20, Iss. 7, pp. 899-906
Closed Access | Times Cited: 4
Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy
Sarah Hamidi, Matthew S. Ning, Jack Phan, et al.
JCEM Case Reports (2025) Vol. 3, Iss. 2
Open Access
Sarah Hamidi, Matthew S. Ning, Jack Phan, et al.
JCEM Case Reports (2025) Vol. 3, Iss. 2
Open Access
Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
Shanmin Fan, Yuan Yang, Yanfang Su, et al.
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access
Shanmin Fan, Yuan Yang, Yanfang Su, et al.
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access
Advances in Diagnosis and Treatment of Radioactive Iodine Refractory Differentiated Thyroid Cancer
Yongji Jiang, Chao Ma, Renfei Wang, et al.
IntechOpen eBooks (2025)
Closed Access
Yongji Jiang, Chao Ma, Renfei Wang, et al.
IntechOpen eBooks (2025)
Closed Access
The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs
Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Ginesa García‐Rostán
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3663-3663
Open Access
Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Ginesa García‐Rostán
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3663-3663
Open Access
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies
Atish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008505-e008505
Open Access | Times Cited: 3
Atish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008505-e008505
Open Access | Times Cited: 3
Emerging Strategies in Thyroid Cancer Immunotherapy: A Comprehensive Systematic Review and Meta-Analysis of Clinical Outcomes
Daniel Alejandro Estrella Cornejo, Meylin Yalitza Carriel Alvarado, Norma Susana Chávez Villagómez, et al.
Salud Ciencia y Tecnología (2024) Vol. 4, pp. 1241-1241
Closed Access | Times Cited: 2
Daniel Alejandro Estrella Cornejo, Meylin Yalitza Carriel Alvarado, Norma Susana Chávez Villagómez, et al.
Salud Ciencia y Tecnología (2024) Vol. 4, pp. 1241-1241
Closed Access | Times Cited: 2
FN1, a reliable prognostic biomarker for thyroid cancer, is associated with tumor immunity and an unfavorable prognosis
Huili Pan, Zhiyan Luo, Lin Feng, et al.
Oncology Letters (2024) Vol. 28, Iss. 5
Open Access | Times Cited: 2
Huili Pan, Zhiyan Luo, Lin Feng, et al.
Oncology Letters (2024) Vol. 28, Iss. 5
Open Access | Times Cited: 2
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma
Kartik Sehgal, Θεοδώρα Παππά, Kee‐Young Shin, et al.
JAMA Oncology (2024)
Closed Access | Times Cited: 2
Kartik Sehgal, Θεοδώρα Παππά, Kee‐Young Shin, et al.
JAMA Oncology (2024)
Closed Access | Times Cited: 2
Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors
Bogdanova Ti, Tatiana Rogounovitch, Liudmyla Zurnadzhy, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 1
Bogdanova Ti, Tatiana Rogounovitch, Liudmyla Zurnadzhy, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 1
Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma
Shereen Ezzat, Jesse D. Pasternak, Murali Rajaraman, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Shereen Ezzat, Jesse D. Pasternak, Murali Rajaraman, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
Daniela Dias, Inês Damásio, Pedro Marques, et al.
European Thyroid Journal (2023) Vol. 12, Iss. 3
Open Access | Times Cited: 3
Daniela Dias, Inês Damásio, Pedro Marques, et al.
European Thyroid Journal (2023) Vol. 12, Iss. 3
Open Access | Times Cited: 3
Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment
Lili Guo, Yue Su, Xiaoyu Liu, et al.
Oncology Letters (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 3
Lili Guo, Yue Su, Xiaoyu Liu, et al.
Oncology Letters (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 3
Calcaneus metastasis: a rare presentation of poorly differentiated thyroid cancer
Omayma Elshafie, Anjali Jain, Summit Bichpuria, et al.
Endocrinology Diabetes and Metabolism Case Reports (2023) Vol. 2023, Iss. 4
Open Access | Times Cited: 2
Omayma Elshafie, Anjali Jain, Summit Bichpuria, et al.
Endocrinology Diabetes and Metabolism Case Reports (2023) Vol. 2023, Iss. 4
Open Access | Times Cited: 2
Immuntherapie von Schilddrüsenkarzinomen
Markus Essler
Angewandte Nuklearmedizin (2024) Vol. 47, Iss. 01, pp. 22-29
Closed Access
Markus Essler
Angewandte Nuklearmedizin (2024) Vol. 47, Iss. 01, pp. 22-29
Closed Access
Immuntherapie von Schilddrüsenkarzinomen
Markus Essler
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 06, pp. 387-394
Closed Access
Markus Essler
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 06, pp. 387-394
Closed Access
Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers
Alessandro Prete, Carmelo Nucera
Current Opinion in Endocrine and Metabolic Research (2024) Vol. 37, pp. 100544-100544
Closed Access
Alessandro Prete, Carmelo Nucera
Current Opinion in Endocrine and Metabolic Research (2024) Vol. 37, pp. 100544-100544
Closed Access
Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol
Anna Lawless, Shejil Kumar, Jessica Bindra, et al.
Asia-Pacific Journal of Clinical Oncology (2024) Vol. 20, Iss. 6, pp. 681-689
Open Access
Anna Lawless, Shejil Kumar, Jessica Bindra, et al.
Asia-Pacific Journal of Clinical Oncology (2024) Vol. 20, Iss. 6, pp. 681-689
Open Access
Leptin and insulin synergize with PIK3CA mutation to enhance PD-L1 mediated immunosuppression in thyroid cancer
Kainan Wu, Yuerong Chen, Runsheng Guo, et al.
Experimental Cell Research (2024) Vol. 442, Iss. 2, pp. 114229-114229
Closed Access
Kainan Wu, Yuerong Chen, Runsheng Guo, et al.
Experimental Cell Research (2024) Vol. 442, Iss. 2, pp. 114229-114229
Closed Access
Le cancer thyroïdien différencié réfractaire à l’iode : quelle prise en charge en 2024 ?
Christine Do Cao, Antoine Danais, Paul Schwartz, et al.
Bulletin du Cancer (2024) Vol. 111, Iss. 10, pp. 10S31-10S41
Closed Access
Christine Do Cao, Antoine Danais, Paul Schwartz, et al.
Bulletin du Cancer (2024) Vol. 111, Iss. 10, pp. 10S31-10S41
Closed Access
A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer Patients
Haihong Yu, Junquan Zeng, Jin-Hua Yuan, et al.
Research Square (Research Square) (2023)
Open Access
Haihong Yu, Junquan Zeng, Jin-Hua Yuan, et al.
Research Square (Research Square) (2023)
Open Access
Radioiodine Refractory Thyroid Cancer
Fabián Pitoia, Anabella Smulever, Fernando Jerkovich
Springer eBooks (2023), pp. 165-188
Closed Access
Fabián Pitoia, Anabella Smulever, Fernando Jerkovich
Springer eBooks (2023), pp. 165-188
Closed Access
